Scenic Biotech Partners with Alnylam to Advance RNAi Therapeutics Using Cell-Seq Platform
This collaboration represents Scenic Biotech’s third Cell-Seq collaboration with major US biotech and pharmaceutical companies, following ongoing multi-year agreements with Genentech and Bristol Myers Squibb. <br />
Cell-Seq Platform | 26/08/2025 | By Dineshwori | 186
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy